Grazoprevir/ruzasvir/uprifosbuvir

Drug Profile

Grazoprevir/ruzasvir/uprifosbuvir

Alternative Names: MK-3682B; MK-5172/MK-3682/MK-8408; MK3

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antivirals; Macrocyclic compounds; Small molecules; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis C

Most Recent Events

  • 17 Aug 2017 Phase-III clinical trials in Hepatitis C in France (PO) (EudraCT2017-001463-21)
  • 19 Apr 2017 Interim efficacy and adverse events data from two phase II trials in Hepatitis C infection presented at The International Liver Congress 2017 (ILS-2017)
  • 19 Apr 2017 Pooled safety and efficacy data from the phase II CREST 1 and 2 trial in hepatitis C presented at The International Liver Congress 2017 (ILC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top